Literature DB >> 8856830

Alprazolam, caffeine and their interaction: relating DRL performance to pharmacokinetics.

C E Lau1, J Wang.   

Abstract

Three-hour sessions of differential reinforcement of low-rate behavior (DRL 45-s) in rats were used to investigate alprazolam, caffeine, and their interactions at the onset, peak and disappearance of serum alprazolam, while caffeine level remained constant. The dose-response curve (DRC) method of Pöch permitted an extensive evaluation of the kind (additivity or independence) of interactions occurring in combined drug effects. The alprazolam and caffeine DRCs were used to derive theoretical additive and independent relations, and the observed combined effects compared to these functions. Behavior-time profiles of the combined effects were similarly compared. Serum alprazolam and caffeine concentrations correlated with their respective behavior-time profiles. No acute tolerance was observed either for the individual drugs or their combinations. Alprazolam was more potent than caffeine in disrupting DRL behavior. Because alprazolam is much shorter-lived (t1/2 = 32 min) than caffeine (t1/2 = 3 h) in rats, potency ratios between alprazolam and caffeine changed across session time (from 123 to 4), which determined the expression of the combined effects. Although the combined effects were not distinguishable in terms of additivity or independence in both the DRCs and in the behavior-time profiles, they showed neither synergism nor antagonism. The pharmacokinetics of alprazolam were not altered by caffeine, but those of caffeine were affected by alprazolam.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856830     DOI: 10.1007/bf02246346

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  Evaluation of combined effects in dose-response studies by statistical comparison with additive and independent interactions.

Authors:  G Pöch; P Dittrich; S Holzmann
Journal:  J Pharmacol Methods       Date:  1990-12

2.  Stimulation of caffeine metabolism in the rat by 3-methylcholanthrene.

Authors:  A Aldridge; W D Parsons; A H Neims
Journal:  Life Sci       Date:  1977-10-01       Impact factor: 5.037

3.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

4.  Use of DRL in differentiating anxiolytic and neuroleptic properties of CNS drugs.

Authors:  J G Canon; A S Lippa
Journal:  Pharmacol Biochem Behav       Date:  1977-05       Impact factor: 3.533

5.  Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo.

Authors:  G B Kaplan; N T Tai; D J Greenblatt; R I Shader
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Interaction between effects of caffeine and lorazepam in performance tests and self-ratings.

Authors:  S E File; A J Bond; R G Lister
Journal:  J Clin Psychopharmacol       Date:  1982-04       Impact factor: 3.153

Review 7.  Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression.

Authors:  G W Dawson; S G Jue; R N Brogden
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

8.  Interactions of diazepam and caffeine: behavioral and subjective dose effects in humans.

Authors:  J D Roache; R R Griffiths
Journal:  Pharmacol Biochem Behav       Date:  1987-04       Impact factor: 3.533

Review 9.  Clinical pharmacokinetics of alprazolam. Therapeutic implications.

Authors:  D J Greenblatt; C E Wright
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

10.  Caffeine increases its own metabolism through cytochrome P4501A induction in rats.

Authors:  F Berthou; T Goasduff; Y Dréano; J F Ménez
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

View more
  1 in total

1.  Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics.

Authors:  C E Lau; F Ma; Y Wang; C Smith
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.